Vaxxinova
Veterinary vaccinology and diagnostics company focused on development, manufacture and deployment of licensed and autogenous (custom) vaccines for poultry, aquaculture, bovine and swine, combined with laboratory diagnostic services, strain-typing and field vaccination support. The organisation provides R&D for antigen selection and attenuation, in vitro and in vivo quality control, and regulatory interaction for country-specific autogenous vaccine approvals.
Industries
Nr. of Employees
medium (51-250)
Vaxxinova
1520 Prairie Drive, Worthington, MN 56187 (Administration – Newport Labs)
Products
Attenuated live Eimeria vaccines for poultry
Live attenuated vaccines containing multiple Eimeria species/strains intended for early-life administration (spray/ocular) and designed to induce gut cellular immunity and field recycling.
SRP-based bacterial antigen vaccines
Vaccines based on siderophore receptor and porin proteins intended to provide cross-serotype protection against bacterial pathogens in poultry and other species.
Autogenous bacterial vaccines for aquaculture (tilapia)
Custom-made inactivated bacterial vaccines produced from field isolates for tilapia, formulated with oil adjuvants and validated by in vitro and in vivo testing.
Attenuated live Eimeria vaccines for poultry
Live attenuated vaccines containing multiple Eimeria species/strains intended for early-life administration (spray/ocular) and designed to induce gut cellular immunity and field recycling.
SRP-based bacterial antigen vaccines
Vaccines based on siderophore receptor and porin proteins intended to provide cross-serotype protection against bacterial pathogens in poultry and other species.
Autogenous bacterial vaccines for aquaculture (tilapia)
Custom-made inactivated bacterial vaccines produced from field isolates for tilapia, formulated with oil adjuvants and validated by in vitro and in vivo testing.
Services
Diagnostic-driven development and manufacturing of autogenous vaccines from field isolate to finished product for aquaculture, poultry, bovine and swine.
Isolation, identification and molecular characterisation of pathogens (culture, MALDI-TOF, PCR, sequencing) plus sample submission logistics and diagnostic reporting.
Application method guidance, vaccination auditing, post-vaccination monitoring and training for hatchery and on-farm vaccination practices.
Systematic sampling and analysis to track field pathogen prevalence and support vaccination program design and shed ‘cooling’ strategies.
Diagnostic-driven development and manufacturing of autogenous vaccines from field isolate to finished product for aquaculture, poultry, bovine and swine.
Isolation, identification and molecular characterisation of pathogens (culture, MALDI-TOF, PCR, sequencing) plus sample submission logistics and diagnostic reporting.
Application method guidance, vaccination auditing, post-vaccination monitoring and training for hatchery and on-farm vaccination practices.
Systematic sampling and analysis to track field pathogen prevalence and support vaccination program design and shed ‘cooling’ strategies.
Expertise Areas
- Autogenous (custom) vaccine production
- Veterinary diagnostic laboratory services
- Poultry vaccine development and field implementation
- Aquatic (tilapia) vaccine development
Key Technologies
- Multiplex PCR
- Microsatellite-based strain typing
- Whole-genome sequencing
- MALDI-TOF mass spectrometry
News & Updates
Announcement of acquisition of Deltamune (Pty) Ltd, a company with in-house R&D and production capabilities for licensed and autogenous vaccines covering Sub-Saharan Africa.
Acquisition of a poultry vaccine portfolio and transfer of an R&D team and pipeline from a prior owner to expand licensed product offerings.
Company announcement marking cumulative sales of over one billion doses of SRP-based vaccines.
Presentation of progress and promising results from vaccine prototypes against Tenacibaculum finnmarkense for aquatic health.
Reported cumulative global sales exceeding one billion doses for SRP-based vaccine products.
Announcement of acquisition of Deltamune (Pty) Ltd, a company with in-house R&D and production capabilities for licensed and autogenous vaccines covering Sub-Saharan Africa.
Acquisition of a poultry vaccine portfolio and transfer of an R&D team and pipeline from a prior owner to expand licensed product offerings.
Company announcement marking cumulative sales of over one billion doses of SRP-based vaccines.
Presentation of progress and promising results from vaccine prototypes against Tenacibaculum finnmarkense for aquatic health.
Reported cumulative global sales exceeding one billion doses for SRP-based vaccine products.